Jean‐Pascal Machiels

Author

Also Known As

J P Machiels, J-P Machiels, JEAN-PASCAL MACHIELS, Jean-Pascal Machiels, Jean‐Pascal Machiels, Leemans, C. RenÃ©, Machiels J. P.

123

Publications

6.7K

Citations

H-Index

Concepts

All Affiliations

Cliniques Universitaires Saint-Luc UCLouvain Institut Gustave Roussy KU Leuven Université Paris-Saclay

About

Jean‐Pascal Machiels is an author at Cliniques Universitaires Saint-Luc specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	14	17	4.9K
2	Health Sciences	2	2	69
3	Immunology	2	2	96
4	Cell Biology	1	1	17
5	Head And Neck Surgery	1	1	71

Jean‐Pascal Machiels

Publications

4.2K

Citations

H-Index

Page 1

	Year	Citations
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study Ezra E.W. Cohen, Denis Soulières, Christophe Le Tourneau, The Lancet MedicinePathologyHead And Neck CancerCancer TreatmentNeck Oncology	2018	1.6K
Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial Thomas Powles, Tibor Csőszi, Mustafa Özgüroğlu, The Lancet Oncology First-line TherapyUrologyChemotherapy Versus ChemotherapyGenitourinary CancerMedicine	2021	627
Trastuzumab for Patients With Axillary-Node–Positive Breast Cancer: Results of the FNCLCC-PACS 04 Trial M. Spielmann, Henri Roché, T. Delozier, Journal of Clinical Oncology	2009	298
A Phase I/II, Multiple-Dose, Dose-Escalation Study of Siltuximab, an Anti-Interleukin-6 Monoclonal Antibody, in Patients with Advanced Solid Tumors Eric Angevin, Josep Tabernero, Élena Elez, Clinical Cancer Research	2014	198
Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial Daniel P. Petrylak, Ronald de Wit, Kim N., The Lancet Platinum-based TherapyUrologyMetastatic Urothelial CarcinomaGenitourinary CancerMedicine	2017	175
Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study Shubham Pant, Martin Schüler, Gopa Iyer, The Lancet Oncology Fgfr AlterationsMedicinePathologyAdvanced Solid TumoursFibroblast Growth Factor	2023	175
Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research and Treatment of Cancer (EORTC) Network Of Core Institutes (NOCI) Patrick Schöffski, Jean‐Yves Blay, Jacques De Grève, European Journal of Cancer OncologyMedicinePathologyImmune Checkpoint InhibitorBreast Cancer	2010	109
Neoadjuvant chemotherapy followed by surgery and adjuvant chemotherapy in patients with primarily unresectable, advanced-stage ovarian cancer F Mazzeo, Martine Berlière, Joseph Kerger, Gynecologic Oncology Surgical OncologyAdvanced-stage Ovarian CancerNeoadjuvant ChemotherapyGynecological SurgeryMedicine	2003	107
A phase 1 dose escalation study of the oncolytic adenovirus enadenotucirev, administered intravenously to patients with epithelial solid tumors (EVOLVE) Jean‐Pascal Machiels, Ramón Salazar, Sylvie Rottey, Journal for ImmunoTherapy of Cancer	2019	100
Chemotherapy: friend or foe to cancer vaccines? Leisha A. Emens, Jean‐Pascal Machiels, R. Todd Reilly, PubMed ImmunologyPathologyImmunotherapyCancer ChemotherapySynthetic Immunology	2001	79

Page 1